uspto-grants-1989_05
uspto-grants-1989_05 · 10.6084/m9.figshare.5104873.v1 · US04826963
查看条件与参与物IDENTITY
COMPUTED
PROPERTIES
115 - 117 °C
Solid
161.54 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards];175.72 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards];155.27 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
164.3 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
PHARMACOLOGY
M - Musculo-skeletal system;M05 - Drugs for treatment of bone diseases;M05B - Drugs affecting bone structure and mineralization;M05BX - Other drugs affecting bone structure and mineralization;M05BX01 - Ipriflavone
QM - Musculo-skeletal system;QM05 - Drugs for treatment of bone diseases;QM05B - Drugs affecting bone structure and mineralization;QM05BX - Other drugs affecting bone structure and mineralization;QM05BX01 - Ipriflavone
Ipriflavone has known human metabolites that include 4H-1-Benzopyran-4-one, 3-(4-hydroxyphenyl)-7-(1-methylethoxy)-, 7-Hydroxyisoflavone, and 3-Phenyl-7-(1-methyl-2-hydroxyethoxy)-4H-1-benzopyran-4-one.
Membrane
ALIASES
REACTIONS
uspto-grants-1989_05
uspto-grants-1989_05 · 10.6084/m9.figshare.5104873.v1 · US04826963
查看条件与参与物uspto-grants-1989_05
uspto-grants-1989_05 · 10.6084/m9.figshare.5104873.v1 · US04826963
查看条件与参与物uspto-grants-1989_05
uspto-grants-1989_05 · 10.6084/m9.figshare.5104873.v1 · US04826963
查看条件与参与物uspto-grants-1991_08
uspto-grants-1991_08 · 10.6084/m9.figshare.5104873.v1 · US05043326
查看条件与参与物uspto-grants-1991_08
uspto-grants-1991_08 · 10.6084/m9.figshare.5104873.v1 · US05043326
查看条件与参与物uspto-grants-1991_08
uspto-grants-1991_08 · 10.6084/m9.figshare.5104873.v1 · US05043326
查看条件与参与物